Patients with either hereditary or acquired thrombophilia can present with arterial and venous thrombotic complications. However, it is unclear to whom the thrombophilia panel should be assessed, particularly in patients presenting with a common cardiovascular risk factor and acute coronary thrombus. Herein, we presented the management of an active smoker female patient who presented to our emergency room with inferior acute ST-segment elevation myocardial infarction, and hereditary thrombophilia has been diagnosed due to the presence of substantial left main coronary artery (...) thrombus. (shrink)

Flew strongly defends a compatibilist thesis in the free will debate before going on to totally object to theistic libertarianism. His objections basically rely on his compatibilism embracing the notion of agent causation, which is not very common in compatibilist theses. Since he is a strong proponent of ordinary language philosophy, he also holds that linguistic analyses can certainly solve the free will problem as well as many other problems of philosophy. In doing so, he first uses the paradigm cases (...) based on our common sense experience and then assumes the verity of principle of alternative possibilities. This study attempts to show, on the one hand, that there are some serious difficulties in both his justification of compatibilism and his objections to theistic libertarianism, and on the other hand, that he cannot easily defend both at the same time. (shrink)

The problem of determinism and human freedom, which is one of the great debates in philosophy, has been discussed many times by philosophers who have very distinctive perspectives and thereby different results related to the problem. Charles Hartshorne as an American process philosopher has significantly contributed to the debate with his own thoughts and considerations. His thoughts can be divided into two major parts. First is the claim that there is a relative indeterminism within the universe. Second is that (hard) (...) determinist and compatibilist positions have serious theoretical and practical difficulties. This paper is only about second part of his thoughts related to the debate. So, in this paper, firstly, I attempt to depict and examine his objections to the arguments for determinism and compatibilism. And then, secondly, I try to interrogate two fundamental assumptions behind his objections. One is the fallacy of burden of proof and other is a fallacy based on the appeal to common sense in order to prove any factual or metaphysical assertion. (shrink)

Interaction between drivers and pedestrians is often facilitated by informal communicative cues, like hand gestures, facial expressions, and eye contact. In the near future, however, when semi- and fully autonomous vehicles are introduced into the traffic system, drivers will gradually assume the role of mere passengers, who are casually engaged in non-driving-related activities and, therefore, unavailable to participate in traffic interaction. In this novel traffic environment, advanced communication interfaces will need to be developed that inform pedestrians of the current state (...) and future behavior of an autonomous vehicle, in order to maximize safety and efficiency for all road users. The aim of the present review is to provide a comprehensive account of empirical work in the field of external human–machine interfaces for autonomous vehicle-to- pedestrian communication. In the great majority of covered studies, participants clearly benefited from the presence of a communication interface when interacting with an autonomous vehicle. Nevertheless, standardized interface evaluation procedures and optimal interface specifications are still lacking. (shrink)

Dear Colleagues, -/- The statement made by Journal Citation Reports on 26 July 2022, it was reported that some important updates in the journal metrics will be published in 2023 [1]. The most striking of these changes was that the journal impact factor would now be calculated, including journals from the Arts and Humanities Citation Index (AHCI) and the Emerging Sources Citation Index (ESCI). -/- On 28 June 2023, the current metrics of the journals indexed in the Web of Science (...) were shared by the Journal Citation Reports for 2022 [2]. As it is known, the European Journal of Therapeutics is indexed in the ESCI and is included in the Category of Medicine, General & Internal. Therefore, the impact factor was calculated for the European Journal of Therapeutics for the first time. -/- According to the report recently announced by Journal Citation Reports, the impact factor of the European Journal of Therapeutics for 2022 is 0.3 (Fig. 1) [3]. In addition, the European Journal of Therapeutics ranks ninetieth among one hundred fifty-seven (90/157) in the Category of Medicine, General & Internal, and ESCI-indexed journals [4]. -/- Although the first impact factor declared for the European Journal of Therapeutics is 0.3 is not a bad value, it is an inevitable reality that it should be better. On the other hand, in previous editorials [5, 6], it was reported that the articles accepted in the European Journal of Therapeutics were now published as Accepted / Early Views Articles quickly [6]. In addition, it was stated that the editorial team was enriched with many internationally important academicians in their fields [5]. Moreover, there will be various revisions and improvements planned to be made to the journal's publication policy in the near future. -/- We think these improvements may play an essential role in increasing the impact factor of the European Journal of Therapeutics in the long term. -/- Yours sincerely. (shrink)

Dear Colleagues, -/- We are delighted to share the new issue (June 2023, volume 29, Issue 2) of the European Journal of Therapeutics (Eur J Ther). Furthermore, we are honored to be appointed as the New Editor-in-Chief and New Deputies Editor-in-Chief of Eur J Ther, the international publication of the Gaziantep University Faculty of Medicine published since 1990. -/- First, we would like to thank the previous Editor-in-Chief, Prof. M. Murat Sucu, and his team for their hard work during their (...) tenure. They significantly increased its contribution to the field and international reputation by further developing the journal. -/- In addition, we would like to express our gratitude to all the editors, authors, referees, and technical team who have contributed to the journal since 1990, when our journal first started being published. -/- Unfortunately, due to the change of publishing house, there were some technical problems and interruptions on the web page of Eur J Ther in the first few months of 2023. So, we regret to inform you that there are delays in the evaluation stages of some manuscripts sent to the journal. However, we would like to let you know that from now on, your valuable works submitted to Eur J Ther will be evaluated as quickly as possible. In addition, we would like to announce that all articles accepted for publication in our journal, which is considered an essential innovation, will be published on the web page of our journal as Early View / Accepted Articles in a short time. This innovation will expedite the citation process for your publications. -/- As the New Editor-in-Chief and New Deputies Editor-in-Chief, we aim to increase the quality and visibility of Eur J Ther and to improve its indexes. -/- We want to remind you that the journal’s target audience is researchers, physicians, and health professionals interested in or working in all medical and dental disciplines. Therefore, we request you submit your valuable research to Eur J Ther to contribute to the development and content of the journal. -/- Sincerely yours,. (shrink)

Dear Colleagues, -/- In this editorial, we would like to share with you important developments in the European Journal of Therapeutics (Eur J Ther). -/- First of all, as the editorial team, we would like you to know that we hold frequent meetings to benefit our esteemed colleagues and continue to work with great devotion in line with our goal of taking the journal further. We have previously shared with you that we have applied to many indexes. It is with (...) great pleasure that we would like to inform you that in the last few months, more of our index applications have been approved. -/- Index Copernicus, as a result of this application, the ICV 2022 value of our journal was determined to be 100 (approved 2023-10-31) [1] BASE (Bielefeld Academic Search Engine) (approved 2023-11-30) [2] Sherpa Romeo (approved 2023-09-27) [3] MIAR (approved 2023-10-16) [4] -/- All indexes in our journal are currently included on the journal web page [5]. -/- As the editorial team, we would like to inform you that we have determined a policy on this issue for our journal [6], taking into account the recommendations of important international ethics committees such as the Committee on Publication Ethics (COPE) [7] and the World Association of Medical Editors (WAME) [8], which have recently become a trendy topic of discussion about AI chatbots and academic studies prepared with the support of such tools. -/- As you know, when our journal was founded in 1990 [9], it was published in two yearly issues. It is an essential responsibility for us to carry our journal, which continued its publication life with three issues a year in 2009 [10] and four issues a year in 2014 [11]. With your valuable support, we would like to announce that we will increase our journal to 6 issues a year as of 2024 (February, April, June, August, October and December) with the rapidly growing progress of our journal. -/- Unfortunately, we cannot share the names of the referees who made significant contributions to our journal in 2023 due to the changes in the article submission interface during the year and the inaccessibility of some data in the previous interface. However, we would like to emphasize again that we are grateful to all of them for their valuable contributions. Moreover, to expand our journal's referee list, we would like to remind you that competent academics who volunteer in this regard can fill out the “Become a Reviewer for the European Journal of Therapeutics” form [12]. -/- Finally, we would like to point out that we have strengthened our editorial team with an academician competent in dentistry, Fatih Sari, DDS, PhD. -/- Fatih Sari, DDS, PhD, is a new Editorial Board Member of the Eur J Ther. Dr. Sari is an Associate Professor in the Department of Prosthodontics at the Gaziantep University Faculty of Dentistry. He is a Vice Dean of the Faculty of Dentistry and Head of Clinical Departments. Dr. Sari is a prosthodontist and a member of the Turkish Dental Association. He has experience in implant-supported fixed prostheses, Cad/Cam applications and dental materials. -/- We look forward to being able to offer you a large number of high-quality and valuable articles over the coming year. In addition, we would like to thank the readers, authors and reviewers of the Eur J Ther for their continuous support. -/- Sincerely yours,. (shrink)

Objective: The objective of this study was to evaluate the clinical efficacy and appropriateness of colistin therapy in patients with hematological malignancies. -/- Methods: Age, gender, type of hematologic malignancy, and potential carbapenem-resistant microorganism risk factors were all noted in this retrospective study. In empirical and agent-specific treatment groups, differences in demographic features, risk factors, treatment responses, and side effects were compared. -/- Results: Sixty-three patients were included, 54% were male, and the median age was 49. In the last three (...) months, the hospitalization rate history was 68%, and four patients had a hospitalization history in the ICU. Carbapenem-resistant K. pneumoniae colonization was present in 22 patients (35%). Gram-negative microorganisms were isolated in 34 patients (54%). The carbapenem, quinolone, and colistin resistance rates were 82%, 76%, and 4% respectively. Clinical and microbiological response rates were 60% and 69%. 7 and 28-day mortality rates were 17% and 35%. There was no significant difference in demographic data and comorbidities in empirical (n=48) and agent-specific (n=15) treatment groups. The rate of carbapenem and glycopeptide treatments before colistin was higher in the empirical treatment group (p = 0.004; p = 0.001). The rate of starting combined antibiotics was higher in the empirical treatment group (p = 0.016). Two of the patients developed renal failure in the first week after treatment. -/- Conclusion: The use of empirical colistin may be unavoidable given the risk considerations. Shortly, colistin-resistant strains may also be a factor affecting treatment success negatively. (shrink)

Coronary artery vasospasm (CAVS) is a clinical entity that can cause angina, but also unstable angina pectoris, acute myocardial infarction, fatal arrhythmias, and sudden death. Although it is a condition that is usually controlled with medical treatment, more aggressive treatments may rarely be required. In this case, the patient with a known diagnosis of CAVS had multiple arrests despite optimal medical treatment. We observed that fatal arrhythmias persisted in the Implantable Cardioverter Defibrillator (ICD) records, even though we implanted a stent (...) and gave the patient maximal medical treatment. We performed sympathectomy as a last resort and we did not detect any recurrence in the 6-month follow-up of the patient. ICD implantation and sympathectomy should always be considered in resistant CAVS cases. (shrink)

Eser, yazarın 2008 yılında tamamlamış olduğu “Kur’an’ın Tasdik Ettiği Tevrat’taki Konular” isimli doktora tezinin 2011 yılında “Tevrat’ın Kur’an’a Arzı-Kur’an’ın Tevrat’ta Tasdik Ettiği Konular” ismiyle basılmasıyla yayın hayatına kazandırılmıştır. Kur’an ve Tevrat’taki konular bu çalışmanın öncesinde ve sonrasında genellikle mukayeseli bir biçimde çalışılmıştır. Gerek Kur’an ve Tefsir alanında gerekse Dinler Tarihi alanında kıssalar, tarihi olaylar, hükümler, uygulamalar gibi pek çok açıdan Kur’an ve Tevrat’a dair özellikle mukayese içeren tezler ve eserler bulunmaktadır. Bu çalışmanın alandaki diğer eserlerden farkı Kur’an’ın Tevrat’ı tasdik edici (...) olmasının ne mânaya geldiğini izah etmesi ve Tevrat’ta yer alan hangi konuları doğrulayıcı olduğunu derli toplu bir şekilde ortaya koymasıdır. (shrink)